Chemeleon Inc. is a diagnostics startup pioneering BINDS™ (Binding-Induced Nanostructured Dynamic Surface), a patented nanotechnology platform for instrument-free, ultra-rapid point-of-need testing. Delivering visible color-change results in <1 minute with no power, prep, or magnification, BINDS achieves 5 ng/L LOD, 10-log dynamic range, 97-99% sensitivity, and 91-100% specificity across proteins, nucleic acids, and small molecules, with COGS dropping to $0.80 at scale via semiconductor manufacturing for decentralized use in ERs, remote clinics, battlefields, and LMICs. Key assays: hs-cTn for AMI (true 0/1-hr protocols, Mayo trials 2026); beta-2-transferrin for CSF leaks (1-min TAT vs. 4-6 days, 200-chip Mayo LDT order); GFAP/UCH-L1 multiplexing for TBI (Mayo collab); chem-bio toxins (DEVCOM CRADA POC complete, JPEO OTA pitch invite Jan 2026). $2M+ NIH/NSF grants, 28 patents (18 granted), FDA Breakthrough invite. Raising $25M Series A for FDA clearance and scale-up in $50B+ markets.